Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from AngioDynamics ( (ANGO) ) is now available.
On April 2, 2026, AngioDynamics reported fiscal third-quarter 2026 results for the period ended February 28, 2026, posting pro forma net sales of $78.4 million, up 8.9% year on year, driven by 19% Med Tech growth to $37.3 million while Med Device revenue rose 1.1% to $41.1 million. The company delivered its sixth straight quarter of double-digit Med Tech growth, generated adjusted EBITDA of $1.8 million despite a GAAP net loss of $8.1 million, and ended the quarter debt-free with $37.8 million in cash.
Growth was led by Auryon, mechanical thrombectomy products AngioVac and AlphaVac, and the NanoKnife platform, all of which logged high-teens to low-20% sales increases, even as gross margin slipped 110 basis points to 52.9% due to tariffs, inflation and manufacturing transition costs. Reflecting confidence in its strategy and sustained Med Tech momentum, AngioDynamics raised its full-year 2026 guidance for net sales, Med Tech and Med Device growth, adjusted EBITDA and adjusted EPS, while warning that inventory builds tied to planned sterilization-vendor shutdowns could make fiscal 2026 cash flow slightly negative without changing its longer-term positive cash-generation outlook.
The most recent analyst rating on (ANGO) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.
Spark’s Take on ANGO Stock
According to Spark, TipRanks’ AI Analyst, ANGO is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative TTM cash flow) and bearish technicals (below major moving averages with negative MACD). These are partly offset by constructive earnings-call signals, including raised FY2026 revenue and adjusted EBITDA guidance and expectations for full-year cash-flow positivity, while valuation support is limited due to negative earnings and no dividend yield data.
To see Spark’s full report on ANGO stock, click here.
More about AngioDynamics
AngioDynamics, Inc. is a medical technology company focused on restoring healthy blood flow in the vascular system, expanding cancer treatment options and improving patient quality of life. Its portfolio includes the Auryon peripheral atherectomy platform, thrombus management devices such as AlphaVac and AngioVac, and the NanoKnife irreversible electroporation system, with a growing emphasis on higher-margin Med Tech offerings.
Average Trading Volume: 558,955
Technical Sentiment Signal: Hold
Current Market Cap: $492.1M
See more data about ANGO stock on TipRanks’ Stock Analysis page.